Publication Cover
Immunological Investigations
A Journal of Molecular and Cellular Immunology
Volume 31, 2002 - Issue 1
31
Views
2
CrossRef citations to date
0
Altmetric
Original

REPEATED TREATMENT WITH S. AUREUS SUPERANTIGENS EXPANDS THE SURVIVAL RATE OF EHRLICH ASCITES TUMOR BEARING MICE

, , &
Pages 13-28 | Published online: 07 Jul 2009
 

Abstract

The bacterial superantigen Staphylococcal enterotoxin-A (SEA), produced by some strains of Staphylococcus aureus, causes proliferation of cytotoxic T-lymphocytes and cytokine production in vivo. SEA has been shown to be highly efficient for antibody-targeted superantegen immunotherapy for different tumor models. A candidate B-cell superantigen that has received considerable attention these days is staphylococcal protein-A (PA). It has been shown to possess multiple immunological responses. The anti-tumor property of PA is well documented in the literature in various transplantable tumors of rats and mice. In the present study, we have shown that the T-cell superantigen SEA and B-cell superantigen PA induce immunomodulatory and anti-tumor activity which is strongly protentiated by PA+SEA co-administration. Combination treatment with PA and SEA prolongs the immune response in vivo, limits the development of immunological unresponsiveness and promotes maximum anti-tumor effects to tumor carrying animals, as compared with PA or SEA alone. The immune response after combined therapy is characterized by substantially augmented IFN-γ, TNF-α, Nitric oxide and strong CTL activity. Our data demonstrate that combined PA+SEA therapy induces long-term survival of the animals, carrying the Ehrlich ascites tumor.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.